Conivaptan: Potential therapeutic implications in heart failure

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 2, 2008, Pages 137-140

  Chen, Stephen Y ^a   Abrahams, Zuheir ^a   Sokos, George G ^a   Mullens, Wilfried ^a   Hobbs, Robert ^a   Taylor, David O ^a   Gonzalez Stawinski, Gonzalo V ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Department of Thoracic and Cardiovascular Surgery ^*  (United States)

Author keywords

Aquaretic; Congestive heart failure; Conivaptan; Vasopressin receptor antagonists

Indexed keywords

CONIVAPTAN; FUROSEMIDE; LOOP DIURETIC AGENT; OPC 40161; PLACEBO; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; DIURETIC AGENT; HORMONE ANTAGONIST; VASOPRESSIN RECEPTOR;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIURESIS; DRUG MECHANISM; HEART FAILURE; HUMAN; HYPONATREMIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; DRUG ANTAGONISM; DRUG EFFECT; ELECTROLYTE BALANCE; PATENT; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

BENZAZEPINES; CARDIOVASCULAR AGENTS; DIURETICS; HEART FAILURE; HORMONE ANTAGONISTS; HUMANS; PATENTS AS TOPIC; RECEPTORS, VASOPRESSIN; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 51149115115     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008784705403     Document Type: Article

References (25)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115(5): E69-171.
2. Defrances CJ, Podgornik MN. 2004 National Hospital Discharge Survey. Advancedata 2006; 371: 1-19.
3. Gupta S, Neyses L. Diuretic usage in heart failure: A continuing conundrum in 2005. Eur Heart J 2005; 26(7): 644-649.
4. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-216.
5. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147(2): 331-338.
6. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100(12): 1311-1315.
7. Klein L, Gattis WA, Leimberger JD, et al. Prognostic value of hyponatremia in hospitalized patients with worsening heart failure -insights from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME - CHF). J Card Fail 2003; 9(5): S83.
8. Chen SY, Tang WH. Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs 2007; 12(1): 75-95.
9. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1(6): 1385-1390.
10. Christensen BM, Marples D, Jensen UB, et al. Acute effects of vasopressin V2-receptor antagonist on kidney AQP2 expression and subcellular distribution. Am J physiol 1998; 275(2 Pt 2): F285-297.
11. Gheorghiade M, Gattis WA, O'connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004; 291(16): 1963-1971.
12. Udelson JE. Multicenter, randomized double-blind, placebo-controlled, efficacy study on the effects of oral tolvaptan on LV dilatation and function in patients with HF and LV systolic dysfunction. (2005): Program and abstracts from the 9th Annual Scientific Meeting of the Heart Failure Society of America, September 18-21, 2005, Boca Raton, Florida, Recent and late breaking clinical trials.
13. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007; 297(12): 1332-1343.
14. Konstam MA, Gheorghiade M, Burnett JC Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007; 297(12): 1319-1331.
15. Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104(20): 2417-2423.
16. Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a vssopressin antagonist in CHF patients undergoing Exercise) trial. Am Heart J 2003; 145(1): 179-186.
17. Verbalis J, Bisaha J, Smith N. Novel vasopressin V1A and V2 antagnoist (conivaptan) increases seurm sodium concentration and effective water clearance in patients with hyponatremia. Circulation 2004; 110(Suppl. III): 723.
18. Goldsmith SR. Efficacy and safety of conivaptan in acute decompensated heart failure: A dose-ranging pilot study. Program and abstracts from the 10th annual scientific meeting of the heart failure society of america, September 10-13, 2006, Seattle, Washington, Abstract 226 (2006).
19. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol 2006; 290(2): F273-278.
20. Burnett JC, Smith WB, Ouyang J, Zimmer CA, Orlandi C. Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy. J Card Fail 2003; 9(5, Suppl. 1): S12.
21. Koppel, G.A., Guillon, C.D., Miller, M.J.: WO07011878 (2007).
22. Koppel, G.A., Heindel, N.D.: WO07109615 (2007).
23. Bruns, R.F. Jr., Guillon, C.D.G., Heindel, N.D., Koppel, G.A., Miller, M.J.: US20077268125 (2007).
24. Webb, R.L., Shetty, S.S.: WO07051007 (2007).
25. Buechler, K.F., Mcpherson, P.H.: WO07028070 (2007).